F M Investments LLC Raises Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

F M Investments LLC grew its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 28.1% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 17,411 shares of the medical research company's stock after acquiring an additional 3,818 shares during the period. F M Investments LLC's holdings in Amgen were worth $4,538,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of AMGN. Centricity Wealth Management LLC acquired a new stake in shares of Amgen during the fourth quarter valued at about $25,000. Ritter Daniher Financial Advisory LLC DE boosted its position in Amgen by 66.2% during the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock worth $33,000 after buying an additional 51 shares during the period. Synergy Investment Management LLC bought a new stake in Amgen during the 4th quarter worth approximately $34,000. Atala Financial Inc acquired a new position in Amgen in the 4th quarter valued at approximately $34,000. Finally, Heck Capital Advisors LLC acquired a new position in shares of Amgen during the fourth quarter worth $36,000. Institutional investors own 76.50% of the company's stock.

Amgen Stock Up 0.5 %

Shares of NASDAQ:AMGN traded up $1.38 during mid-day trading on Tuesday, hitting $295.30. 2,588,402 shares of the company traded hands, compared to its average volume of 2,777,829. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. The stock has a market cap of $158.77 billion, a P/E ratio of 39.11, a P/E/G ratio of 2.63 and a beta of 0.59. The stock has a 50-day moving average price of $304.05 and a two-hundred day moving average price of $294.91. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85.

Remove Ads

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, equities research analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be issued a $2.38 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.22%. Amgen's dividend payout ratio (DPR) is presently 126.09%.

Insider Activity at Amgen

In other news, EVP Jonathan P. Graham sold 25,045 shares of the firm's stock in a transaction on Friday, February 7th. The stock was sold at an average price of $293.12, for a total value of $7,341,190.40. Following the completion of the transaction, the executive vice president now directly owns 28,987 shares of the company's stock, valued at $8,496,669.44. This trade represents a 46.35 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Nancy A. Grygiel sold 1,589 shares of the company's stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the sale, the senior vice president now owns 7,210 shares in the company, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 69,341 shares of company stock worth $20,644,335. Insiders own 0.69% of the company's stock.

Wall Street Analysts Forecast Growth

AMGN has been the subject of a number of recent research reports. Wells Fargo & Company restated an "equal weight" rating on shares of Amgen in a report on Wednesday, February 5th. Piper Sandler Companies restated an "overweight" rating and set a $310.00 price objective on shares of Amgen in a research report on Thursday, January 2nd. Truist Financial reduced their target price on Amgen from $333.00 to $298.00 and set a "hold" rating on the stock in a report on Wednesday, January 8th. Piper Sandler boosted their price target on shares of Amgen from $310.00 to $329.00 and gave the stock an "overweight" rating in a research report on Monday, February 10th. Finally, StockNews.com upgraded shares of Amgen from a "buy" rating to a "strong-buy" rating in a report on Wednesday, April 9th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $314.91.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.